PPG sells fine chemicals unit to ZaCh Systems

23 September 2007

Pittsburgh, USA-based PPG Industries, a chemicals, paints and coatings firm, has signed an agreement with ZaCh Systems SpA, the fine chemicals subsidiary of Italy's Zambon, to sell the latter its fine chemicals business for around $65.0 million. The transaction, which is expected to complete later this year, includes a book charge to income of less than $0.15 per share. Further terms of the accord were not provided.

PPG facilities included in the agreement are a pharmaceutical fine chemicals plant in LaPorte, Texas, and the PPG-Sipsy facility in Avrille, France. The drug fine chemicals plant in LaPorte operates separately from PPG's adjacent phosgene derivatives facility, of which PPG will retain operation. The fine chemicals business employs approximately 360 people.

"The acquisition of PPG's fine chemicals business is consistent with Zambon Company's continuing desire to expand its global presence," said Gianni Marini, ZaCh System board chairman. "We are quite pleased to acquire a PPG business that is recognized as a technology leader, with manufacturing locations in Europe and the USA, reinforcing our custom synthesis business strategy and the value of Zambon research competence," he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight